The Human Hookworm Vaccine Initiative (HHVI) has identified and produced several candidates for potential use as a vaccine. Currently, two lead candidate antigens are being developed to stimulate the human immune system to produce antibodies that inhibit parasite blood feeding. Phase 1 clinical testing of the Na-GST-1 hookworm vaccine, began in January 2012. Currently clinical trials are being carried out in Minas Gerais, Brazil and Washington, DC.
The development of a successful vaccine is a significant undertaking that takes years to achieve. The Sabin Vaccine Institute Product Development Partnership (PDP) is internationally recognized for its development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, Chagas disease, leishmaniasis and SARS. Sabin PDP esteemed partners include:
With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:
Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.
The Sabin Vaccine Institute PDP works on developing vaccines for the more than 700 million people suffering from hookworm in the world today. Established in 2000 with funding from the Bill & Melinda Gates Foundation, the Sabin PDP (originally the Human Hookworm Vaccine Initiative) is the first and only PDP in the world developing a vaccine for human hookworm infection.
The Sabin PDP is focused on the development of sustainable and cost-effective vaccines for preventing widespread neglected tropical diseases (NTDs), including hookworm, schistosomiasis, Chagas disease and leishmaniasis.
An essential element of the Sabin Vaccine Institute’s mission to reduce human suffering caused by vaccine preventable and neglected tropical diseases (NTDs) is the Sabin Vaccine Institute Product Development Partnership (Sabin PDP), an internationally recognized PDP focused on creating safe, effective, low-cost vaccines for tropical infections in developing countries.
June 27, 2012 | PLoS Neglected Tropical Diseases
Neglected Tropical Diseases as Hidden Causes of Cardiovascular Disease
Yasmin Moolani, Gene Bukhman, Peter J. Hotez
An important component of the burden of cardiovascular disease in low- and middle-income countries may be attributed to the neglected tropical diseases.
May 18, 2012 | Pacific Standard
Ahead of this weekend’s G8 Summit, Dr. Peter Hotez wrote an op-ed for Pacific Standard calling on G8 leaders to focus on NTD treatment and control as a cost-effective method to improve global health.
Reversing the World’s Neglect of Easily Cured Tropical Diseases
Dr. Peter Hotez
April 27, 2012 | Houston Chronicle
Dr. Peter Hotez and his role at Baylor College of Medicine’s School of Tropical Medicine were featured in the Houston Chronicle. The article also mentions the new tropical medicine clinic and the vaccine development programs in Houston and calls attention to Dr. Hotez’s PLoS article about NTDs in Texas and Mexico.
Tropical diseases surfacing more in Texas
By Todd Ackerman